Aquestive therapeutics reports positive results from final two arms of epiphast trial supporting performance and real-world functionality of aqst-109 epinephrine oral film

Warren, n.j., july 11, 2022 (globe newswire) -- aquestive therapeutics, inc. (nasdaq: aqst), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced positive topline results from the final two arms of part 3 of the epiphast study for its aqst-109 epinephrine oral film.
AQST Ratings Summary
AQST Quant Ranking